INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5001, 8033, 'Magnesium sulfate', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5002, 22217, 'Magnesium sulfate', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5003, 22218, 'Magnesium sulfate', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5004, 30953, 'Magnesium sulfate', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5005, 32023, 'Magnesium sulfate', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5006, 3797, 'Magnesium sulfate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5007, 3935, 'Magnesium sulfate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5008, 8033, 'Magnesium sulfate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5009, 22217, 'Magnesium sulfate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5010, 22218, 'Magnesium sulfate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5011, 30953, 'Magnesium sulfate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5012, 32023, 'Magnesium sulfate', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5013, 3797, 'Magnesium sulfate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5014, 3935, 'Magnesium sulfate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5015, 8033, 'Magnesium sulfate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5016, 22217, 'Magnesium sulfate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5017, 22218, 'Magnesium sulfate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5018, 30953, 'Magnesium sulfate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5019, 32023, 'Magnesium sulfate', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5020, 3797, 'Magnesium sulfate', 'Heart Diseases', 'The parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction.  These conditions may be exacerbated during magnesium infusion.  High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L.  If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored.  The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5021, 3935, 'Magnesium sulfate', 'Heart Diseases', 'The parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction.  These conditions may be exacerbated during magnesium infusion.  High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L.  If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored.  The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5022, 8033, 'Magnesium sulfate', 'Heart Diseases', 'The parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction.  These conditions may be exacerbated during magnesium infusion.  High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L.  If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored.  The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5023, 22217, 'Magnesium sulfate', 'Heart Diseases', 'The parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction.  These conditions may be exacerbated during magnesium infusion.  High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L.  If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored.  The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5024, 22218, 'Magnesium sulfate', 'Heart Diseases', 'The parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction.  These conditions may be exacerbated during magnesium infusion.  High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L.  If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored.  The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5025, 30953, 'Magnesium sulfate', 'Heart Diseases', 'The parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction.  These conditions may be exacerbated during magnesium infusion.  High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L.  If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored.  The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5026, 32023, 'Magnesium sulfate', 'Heart Diseases', 'The parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction.  These conditions may be exacerbated during magnesium infusion.  High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L.  If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored.  The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5027, 3797, 'Magnesium sulfate', 'Pre-Eclampsia', 'Intravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5028, 3935, 'Magnesium sulfate', 'Pre-Eclampsia', 'Intravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5029, 8033, 'Magnesium sulfate', 'Pre-Eclampsia', 'Intravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5030, 22217, 'Magnesium sulfate', 'Pre-Eclampsia', 'Intravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5031, 22218, 'Magnesium sulfate', 'Pre-Eclampsia', 'Intravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5032, 30953, 'Magnesium sulfate', 'Pre-Eclampsia', 'Intravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5033, 32023, 'Magnesium sulfate', 'Pre-Eclampsia', 'Intravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5034, 3797, 'Magnesium sulfate', 'Kidney Diseases', 'Magnesium is eliminated by the kidney.  The serum concentration of magnesium is increased in patients with renal impairment.  Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time.  Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication.  Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function.  Clinical monitoring of serum magnesium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5035, 3935, 'Magnesium sulfate', 'Kidney Diseases', 'Magnesium is eliminated by the kidney.  The serum concentration of magnesium is increased in patients with renal impairment.  Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time.  Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication.  Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function.  Clinical monitoring of serum magnesium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5036, 8033, 'Magnesium sulfate', 'Kidney Diseases', 'Magnesium is eliminated by the kidney.  The serum concentration of magnesium is increased in patients with renal impairment.  Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time.  Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication.  Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function.  Clinical monitoring of serum magnesium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5037, 22217, 'Magnesium sulfate', 'Kidney Diseases', 'Magnesium is eliminated by the kidney.  The serum concentration of magnesium is increased in patients with renal impairment.  Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time.  Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication.  Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function.  Clinical monitoring of serum magnesium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5038, 22218, 'Magnesium sulfate', 'Kidney Diseases', 'Magnesium is eliminated by the kidney.  The serum concentration of magnesium is increased in patients with renal impairment.  Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time.  Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication.  Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function.  Clinical monitoring of serum magnesium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5039, 30953, 'Magnesium sulfate', 'Kidney Diseases', 'Magnesium is eliminated by the kidney.  The serum concentration of magnesium is increased in patients with renal impairment.  Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time.  Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication.  Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function.  Clinical monitoring of serum magnesium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5040, 32023, 'Magnesium sulfate', 'Kidney Diseases', 'Magnesium is eliminated by the kidney.  The serum concentration of magnesium is increased in patients with renal impairment.  Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time.  Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication.  Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function.  Clinical monitoring of serum magnesium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5041, 3797, 'Magnesium sulfate', 'Myasthenia Gravis', 'The use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis.  Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure.  Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5042, 3935, 'Magnesium sulfate', 'Myasthenia Gravis', 'The use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis.  Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure.  Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5043, 8033, 'Magnesium sulfate', 'Myasthenia Gravis', 'The use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis.  Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure.  Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5044, 22217, 'Magnesium sulfate', 'Myasthenia Gravis', 'The use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis.  Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure.  Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5045, 22218, 'Magnesium sulfate', 'Myasthenia Gravis', 'The use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis.  Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure.  Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5046, 30953, 'Magnesium sulfate', 'Myasthenia Gravis', 'The use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis.  Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure.  Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5047, 32023, 'Magnesium sulfate', 'Myasthenia Gravis', 'The use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis.  Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure.  Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5048, 3797, 'Magnesium sulfate', 'Arrhythmias, Cardiac', 'The use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias.  There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation.  Patients with electrolyte abnormalities should have them corrected before treatment is initiated.  Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures.  It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5049, 3935, 'Magnesium sulfate', 'Arrhythmias, Cardiac', 'The use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias.  There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation.  Patients with electrolyte abnormalities should have them corrected before treatment is initiated.  Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures.  It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5050, 8033, 'Magnesium sulfate', 'Arrhythmias, Cardiac', 'The use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias.  There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation.  Patients with electrolyte abnormalities should have them corrected before treatment is initiated.  Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures.  It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5051, 22217, 'Magnesium sulfate', 'Arrhythmias, Cardiac', 'The use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias.  There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation.  Patients with electrolyte abnormalities should have them corrected before treatment is initiated.  Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures.  It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5052, 22218, 'Magnesium sulfate', 'Arrhythmias, Cardiac', 'The use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias.  There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation.  Patients with electrolyte abnormalities should have them corrected before treatment is initiated.  Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures.  It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5053, 30953, 'Magnesium sulfate', 'Arrhythmias, Cardiac', 'The use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias.  There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation.  Patients with electrolyte abnormalities should have them corrected before treatment is initiated.  Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures.  It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5054, 32023, 'Magnesium sulfate', 'Arrhythmias, Cardiac', 'The use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias.  There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation.  Patients with electrolyte abnormalities should have them corrected before treatment is initiated.  Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures.  It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5055, 0, 'Mebrofenin', 'Digestive System Diseases', 'Nonvisualization or delayed visualization of the gallbladder may occur in certain populations, including patients who have been fasting for a prolonged period or undergoing parenteral feeding; patients with chronic cholecystitis or pancreatitis; and patients with hepatocellular disease or juvenile hepatitis.  Septic patients may show absent or delayed hepatobiliary clearance.  Therefore, a positive finding does not, by itself, permit a differential diagnosis and should be considered in conjunction with the total clinical picture and results of other diagnostic modalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5056, 805, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5057, 806, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5058, 12227, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5059, 12231, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5060, 12232, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5061, 14222, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5062, 24681, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5063, 24682, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5064, 24770, 'Mebendazole', 'Liver Diseases', 'Although mebendazole is poorly absorbed from the gastrointestinal tract (only 2% to 10% of a dose is absorbed systemically), absorbed drug is primarily metabolized by the liver.  Therapy with mebendazole should be administered cautiously in patients with liver disease.  Liver function tests should be monitored during extended use or high-dose therapy, since elevation of serum transaminases (AST, ALT) and GGT, as well as rare cases of hepatitis, have been reported during prolonged therapy and at dosages substantially above those normally recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5065, 0, 'Mecasermin', 'Diabetes Mellitus, Type 2', 'Mecasermin has insulin-like hypoglycemic effects, therefore, care should be taken when prescribing this agent to diabetic patients.  It is recommended to monitor blood glucose levels in these patients until a well-tolerated dose is established and subsequently as medically indicated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5066, 0, 'Mecasermin', 'Edema due to obstruction of lymph vessels or disorders of the lymph nodes.', 'Lymphoid tissue (e.g., tonsillar and adenoidal) hypertrophy associated with complications such as snoring, sleep apnea, and chronic middle-ear effusions have been reported with the use of mecasermin.  Patients presenting these complications should be periodically examined to rule-out the occurrence of lymphoid tissue hypertrophy.  Care should be taken when prescribing mecasermin to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5067, 0, 'Mecasermin', 'Scoliosis', 'Because mecasermin increases growth rate, patients who experience rapid growth should be closely monitored for any onset of a limp or complaints of hip or knee pain.  Patients with a history of scoliosis who are treated with mecasermin should be monitored for progression of scoliosis.  Care should be taken when prescribing this agent to patients with a history of scoliosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5068, 0, 'Mecasermin', 'Vision Disorders', 'Intracranial hypertension with papilledema, visual changes, headache, nausea and/or vomiting have occurred in patients treated with mecasermin.  Ophthalmologic examination is recommended at the initiation and periodically during the course of mecasermin therapy.  Assessment is recommended prior to prescribing this agent to patients with ocular complications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5069, 0, 'Measles virus vaccine live attenuated', 'Immune Deficiency Disease', 'In general, the use of measles, mumps, and rubella vaccine or any single component is contraindicated in patients with primary or acquired immunodeficiency.  Since these vaccines contain live attenuated viruses, the absence of immune competence may potentiate the replication of vaccine virus, increase adverse host reactions, and compromise serum antibody response.  Likewise, the vaccine should not be administered to anyone with a family history of congenital or hereditary immunodeficiency until the individual''s immune status can be assessed and is determined to be adequate.  In the case of HIV infection, patients without overt clinical manifestations suggesting severe immunodeficiency should be vaccinated because measles can be particularly severe and potentially fatal in the presence of HIV.  However, immunization may be less effective in these patients, and they should be monitored for vaccine-preventable diseases.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5070, 0, 'Measles virus vaccine live attenuated', 'Infections', 'Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure.  However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient''s symptoms and their etiology.  Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial.  In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished.  On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered.  In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops.  In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5071, 0, 'Mechlorethamine', 'Infections', 'The use of mechlorethamine is contraindicated in patients with known infectious diseases.  Mechlorethamine inhibits rapidly proliferating cells and can induce severe myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, and local infection during therapy with mechlorethamine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5072, 0, 'Mechlorethamine', 'Bone Marrow Failure Disorders', 'Mechlorethamine induces leukopenia and thrombocytopenia.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior irradiation or chemotherapy, or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Other unspecified bone marrow abnormalities have been noted during therapy with mechlorethamine in patients with neoplastic disease.  Close clinical monitoring of hematopoietic function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5073, 8617, 'Meclizine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5074, 22430, 'Meclizine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5075, 8617, 'Meclizine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5076, 22430, 'Meclizine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5077, 8617, 'Meclizine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5078, 22430, 'Meclizine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5079, 8617, 'Meclizine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5080, 22430, 'Meclizine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5081, 24890, 'Meclofenamic acid', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5082, 24890, 'Meclofenamic acid', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5083, 24890, 'Meclofenamic acid', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5084, 24890, 'Meclofenamic acid', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5085, 24890, 'Meclofenamic acid', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5086, 24890, 'Meclofenamic acid', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5087, 24890, 'Meclofenamic acid', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5088, 24890, 'Meclofenamic acid', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5089, 24890, 'Meclofenamic acid', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5090, 24890, 'Meclofenamic acid', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5091, 24890, 'Meclofenamic acid', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5092, 24890, 'Meclofenamic acid', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5093, 3420, 'Medroxyprogesterone acetate', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5094, 22484, 'Medroxyprogesterone acetate', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5095, 24423, 'Medroxyprogesterone acetate', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5096, 25441, 'Medroxyprogesterone acetate', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5097, 26575, 'Medroxyprogesterone acetate', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5098, 3420, 'Medroxyprogesterone acetate', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5099, 22484, 'Medroxyprogesterone acetate', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (5100, 24423, 'Medroxyprogesterone acetate', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', '', 'DDInter', 0);
